Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe
Christoph LangeGerman Center for Infection Research (DZIF), Borstel, GermanyRaquel DuartePorto University, Porto, PortugalM. JachymBligny Hospital, Briis-sous-Forges, FranceGunar GuentherGerman Center for Infection Research (DZIF), Borstel, GermanyLorenzo GuglielmettiBligny Hospital, Briis-sous-Forges, FranceIoana D. OlaruGerman Center for Infection Research (DZIF), Borstel, GermanyOlena OliveiraPorto University, Porto, PortugalRudolf RumetshoferOtto Wagner Hospital, Vienna, AustriaNicolas VézirisPitié-Salpêtrière Hospital, Paris, FranceFrank van LethAmsterdam Institute for Global Health and Development, Amsterdam, the Netherlands
2016en
ABI
Annotatsiya
Extract: The emergence of multidrug-resistant tuberculosis (MDR-TB), defined as bacillary resistance to at least rifampicin and isoniazid, threatens global TB control. The number of patients notified with MDR-TB worldwide has increased by 261% from 2009 to 2014, and more than one-third of these patients currently live in the European Region of the World Health Organization (WHO). Management of patients with MDR-TB is challenging owing to the long duration of therapy required to achieve a relapse-free cure, complex drug regimens, frequent drug-related adverse events, high costs, suboptimal adherence, and overall low cure rates. [...]
Hali tarjima qilinmagan
Identifikatorlar
Iqtiboslar va manbalar
2 ta iqtibos0 ta foydalanilgan manba